|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2010-8-13
|
|
pubmed:abstractText |
Carboplatin-based combinations are established in platinum-sensitive recurrent ovarian cancer. To improve the therapeutic index, new platinum-based combinations are required. Pemetrexed is a multi-targeted antifolate inhibiting thymidylate synthase. The aim of this study was to determine the maximally tolerated dose (MTD) and dose-limiting toxicity (DLT) and to characterize toxicities of the combination of pemetrexed (Pem) and carboplatin (Cb).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
1432-0843
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
66
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
861-8
|
|
pubmed:meshHeading |
pubmed-meshheading:20054549-Adult,
pubmed-meshheading:20054549-Aged,
pubmed-meshheading:20054549-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:20054549-Carboplatin,
pubmed-meshheading:20054549-Dose-Response Relationship, Drug,
pubmed-meshheading:20054549-Drug Delivery Systems,
pubmed-meshheading:20054549-Female,
pubmed-meshheading:20054549-Glutamates,
pubmed-meshheading:20054549-Guanine,
pubmed-meshheading:20054549-Humans,
pubmed-meshheading:20054549-Maximum Tolerated Dose,
pubmed-meshheading:20054549-Middle Aged,
pubmed-meshheading:20054549-Neoplasm Recurrence, Local,
pubmed-meshheading:20054549-Ovarian Neoplasms,
pubmed-meshheading:20054549-Prospective Studies
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
A phase-I trial of pemetrexed plus carboplatin in recurrent ovarian cancer.
|
|
pubmed:affiliation |
Department of Obstetrics and Gynecology, Charité University Hospital, Berlin, Germany. sehouli@aol.com
|
|
pubmed:publicationType |
Journal Article,
Multicenter Study,
Clinical Trial, Phase I
|
